#United States #San Francisco #Clinical Trials #Atreo #RTSM

Atreo Marks 100th Study Launch, Accelerating the Shift to Next-Generation RTSM

Atreo, a pioneer in next-generation Randomization and Trial Supply Management (RTSM) technology, proudly announced the successful launch of its 100th study. This remarkable achievement underscores the growing demand from global pharmaceutical companies, biotech firms, and clinical research organizations (CROs) for a more flexible approach to clinical trials, particularly as the industry evolves.

Meeting Modern Expectations

In an era where rapid innovation and adaptability are key, Atreo has established itself as a leader in the RTSM field by offering a solution that breaks free from the constraints of legacy Interactive Response Technology (IRT) systems. Clients are increasingly looking for systems that allow for swift configurations and seamless adaptability, reflecting real-time scientific advancements without the excessive delays and resource needs that have historically bogged down traditional providers.

Ryan Harrison, Co-founder and CEO of Atreo, emphasized the significance of this milestone, stating, "Reaching 100 studies in such a short timeframe isn't just about numbers; it validates our vision. Our strategy was to address the limitations faced by legacy IRT systems through ongoing innovation and a modern service model. With over 70 additional study launches anticipated in 2026, our dedicated but lean team is fully equipped to meet market demands."

A Robust Client Retention Strategy

Atreo's impressive growth can primarily be attributed to the strength and diversity of its client partnerships. Keaton Fonvielle, the Head of Client Services at Atreo, noted that their clientele includes leading global pharmaceutical firms, emerging biotechs, and well-established CROs, with a remarkable 100% client retention rate. This statistic highlights the company's commitment to delivering consistently high-quality service and fostering strong collaborative relationships.

"Our clients trust us with their projects because we ensure they are always supported by RTSM experts, ensuring excellence throughout the process," Fonvielle added.

Transforming Expectations in RTSM

Through continuous innovation, Atreo is reshaping the standards that sponsors should anticipate from their RTSM partners. The company prides itself on offering several key capabilities, including:

• - Faster Study Starts: reducing timelines from protocol approval to First Patient In significantly, ensuring trials commence without delays.
• - Rapid Change Management: implementing system updates in days instead of months, making it easier for teams to adjust to evolving study needs.
• - Expert-Backed Support: ensuring that clients engage with RTSM experts who provide consistent and thorough support, regardless of the project's complexity.

Atreo’s mission is not only to drive technological advancement but to create RTSM solutions that enhance agility, predictability, and quality. This allows clinical teams to concentrate more on patient care rather than administrative hurdles. As Atreo moves forward, its ongoing commitment to innovation and client service positions the company as a key player in the future of clinical trials.

Conclusion

Atreo's success in launching its 100th study is a testament to its innovative ethos and client-first approach in the RTSM landscape. As the dynamics of clinical trials continue to evolve, Atreo remains committed to redefining expectations, empowering sponsors, and ultimately improving patient outcomes through scalable, reliable technology solutions.